急性陰窩性扁桃炎に対するSBTPC (Sultamicillin) の薬効評価

Cefaclorとの二重盲検比較試験

抄録

Sultamicillin (SBTPC) was compared with cefaclor (CCL) and evaluated as for the efficacy and safety in the treatment for 255 patients with acute lacunar tonsillitis in a double blind study. 375mg of SBTPC or 250mg of CCL were administered orally after a meal three times a day. The clinical efficacy rates of SBTPC and CCL were judged by attending doctors to be 91.9% (91/99), and 91.1% (82/90), respectively, and those judged by the committee were 80.8% (80/99), and 75.6% (68/90), respectively. There was no significant difference between SBTPC and CCL. In the patients with severe symptoms, SBTPC showed excellent efficacy in 11 out of 14 patients (78.6%), and CCL in 2 out of 8 patients (25.0%). In the judgment of attending doctors, SBTPC was significantly superior to CCL (P<0.05). The bacteriological effectiveness (eradication rate) was 98.9% (91/92) in SBTPC group and 97.7% (85/87) in CCL group. There was no statistically significant difference between two groups. The rate of side effect occurrence was 2.6% (3/114) in SBTPC group and 0.8% (1/112) in CCL group, with no significant difference between the two groups, no severe side effects were observed in either groups.